158 related articles for article (PubMed ID: 37414632)
1. [Dysimmune manifestations associated with myelodysplastic neoplasms and chronic myelomonocytic leukaemias].
Jachiet V; Hadjadj J; Zhao LP; Chasset F; Fain O; Fenaux P; Mekinian A
Bull Cancer; 2023 Nov; 110(11):1147-1155. PubMed ID: 37414632
[TBL] [Abstract][Full Text] [Related]
2. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study.
Mekinian A; Grignano E; Braun T; Decaux O; Liozon E; Costedoat-Chalumeau N; Kahn JE; Hamidou M; Park S; Puéchal X; Toussirot E; Falgarone G; Launay D; Morel N; Trouiller S; Mathian A; Gombert B; Schoindre Y; Lioger B; De Wazieres B; Amoura Z; Buchdaul AL; Georgin-Lavialle S; Dion J; Madaule S; Raffray L; Cathebras P; Piette JC; Rose C; Ziza JM; Lortholary O; Montestruc F; Omouri M; Denis G; Rossignol J; Nimubona S; Adès L; Gardin C; Fenaux P; Fain O
Rheumatology (Oxford); 2016 Feb; 55(2):291-300. PubMed ID: 26350487
[TBL] [Abstract][Full Text] [Related]
3. [Polymyalgia rheumatic and chronic myelomonocytic leukemia].
Delapierre A; Nganoa C; Maitre E; Briet-Rochoux Q; Maillot F; Aouba A; Audemard-Verger A
Rev Med Interne; 2021 Jun; 42(6):434-437. PubMed ID: 33129580
[TBL] [Abstract][Full Text] [Related]
4. A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Mekinian A; Zhao LP; Chevret S; Desseaux K; Pascal L; Comont T; Maria A; Peterlin P; Terriou L; D'Aveni Piney M; Gourin MP; Vey N; Rauzy OB; Grobost V; Bezanahary H; Dimicoli-Salazar S; Banos A; Wickenhauser S; De Renzis B; Durot E; Natarajan-Amé S; Voillat L; Chermat F; Lemaire K; Jachiet V; Himberlin C; Thépot S; Diaz JMT; Frenzel L; Gyan E; Denis G; Hirsch P; Kosmider O; Ades L; Fain O; Fenaux P
Leukemia; 2022 Nov; 36(11):2739-2742. PubMed ID: 36104395
[No Abstract] [Full Text] [Related]
5. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
6. Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome.
Kataoka A; Mizumoto C; Kanda J; Iwasaki M; Sakurada M; Oka T; Fujimoto M; Yamamoto Y; Yamashita K; Nannya Y; Ogawa S; Takaori-Kondo A
Int J Hematol; 2023 Jun; 117(6):919-924. PubMed ID: 36641501
[TBL] [Abstract][Full Text] [Related]
7. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
[TBL] [Abstract][Full Text] [Related]
8. Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Jachiet V; Ricard L; Hirsch P; Malard F; Pascal L; Beyne-Rauzy O; Peterlin P; Maria ATJ; Vey N; D'Aveni M; Gourin MP; Dimicoli-Salazar S; Banos A; Wickenhauser S; Terriou L; De Renzis B; Durot E; Natarajan-Ame S; Vekhoff A; Voillat L; Park S; Vinit J; Dieval C; Dellal A; Grobost V; Willems L; Rossignol J; Solary E; Kosmider O; Dulphy N; Zhao LP; Adès L; Fenaux P; Fain O; Mohty M; Gaugler B; Mekinian A;
Clin Exp Med; 2023 Jul; 23(3):803-813. PubMed ID: 35953763
[TBL] [Abstract][Full Text] [Related]
9. Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
Martin de Frémont G; Hirsch P; Gimenez de Mestral S; Moguelet P; Ditchi Y; Emile JF; Senet P; Georgin-Lavialle S; Hanslik T; Maurier F; Adedjouma A; Abisror N; Mahevas T; Malard F; Adès L; Fenaux P; Fain O; Chasset F; Mekinian A
Front Immunol; 2021; 12():715053. PubMed ID: 34671345
[TBL] [Abstract][Full Text] [Related]
10. Vasculitis associated with myelodysplastic syndrome and chronic myelomonocytic leukemia: French multicenter case-control study.
Roupie AL; Guedon A; Terrier B; Lahuna C; Jachiet V; Regent A; de Boysson H; Carrat F; Seguier J; Terriou L; Versini M; Queyrel V; Groh M; Benhamou Y; Maurier F; Ledoult E; Clech LL; D'Aveni M; Rossignol J; Galland J; Willems L; Chiche NJ; Peterlin P; Roux-Sauvat M; Parcelier A; Wemeau M; Lambert M; Belizna C; Puechal X; Swiader L; Cohen-Valensi R; Noc V; Dao E; Thepot S; de Frémont GM; Tanguy-Schmidt A; Koka AM; Bussone G; Philipponnet C; Konate A; Cavaille G; Guilpain P; Allain JS; Broner J; Solary E; Ruivard M; de Renzis B; Corm S; Baati N; Schleinitz N; Ponsoye M; Stamatoullas-Bastard A; Ades L; Dellal A; Tchirkov A; Aouba A; Fenaux P; Fain O; Mekinian A;
Semin Arthritis Rheum; 2020 Oct; 50(5):879-884. PubMed ID: 32896704
[TBL] [Abstract][Full Text] [Related]
11. MDM2 antagonist improves therapeutic activity of azacitidine in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Wei Y; Zheng H; Lockyer PP; Darbaniyan F; Li Z; Kanagal-Shamanna R; Soltysiak KA; Yang H; Ganan-Gomez I; Montalban-Bravo G; Chien KS; Do KA; Daver N; Garcia-Manero G
Leuk Lymphoma; 2022 Dec; 63(13):3154-3164. PubMed ID: 36059252
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.
Beguin Y; Selleslag D; Meers S; Graux C; Bries G; Deeren D; Vrelust I; Ravoet C; Theunissen K; Voelter V; Potier H; Trullemans F; Noens L; Mineur P
Acta Clin Belg; 2015 Feb; 70(1):34-43. PubMed ID: 25444072
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
14. A systematic review and meta
Kunacheewa C; Thongthang P; Ungprasert P; Utchariyaprasit E; Owattanapanich W
Hematology; 2019 Dec; 24(1):498-506. PubMed ID: 31221030
[TBL] [Abstract][Full Text] [Related]
15. [Skin manifestations associated with myelodysplastic syndromes].
Morand JJ; Lightburn E; Richard MA; Hesse-Bonerandi S; Carsuzaa F; Grob JJ
Rev Med Interne; 2001 Sep; 22(9):845-53. PubMed ID: 11599186
[TBL] [Abstract][Full Text] [Related]
16. Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Jachiet V; Moulis G; Hadjadj J; Seguier J; Laribi K; Schleinitz N; Vey N; Sacre K; Godeau B; Beyne-Rauzy O; Bouvet R; Broner J; Brun N; Comont T; Gaudin C; Lambotte O; Le Clech L; Peterlin P; Roy-Peaud F; Salvado C; Versini M; Isnard F; Kahn JE; Gobert D; Adès L; Fenaux P; Fain O; Mekinian A
Haematologica; 2021 May; 106(5):1414-1422. PubMed ID: 33626866
[TBL] [Abstract][Full Text] [Related]
17. Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study.
Mądry K; Lis K; Biecek P; Młynarczyk M; Rytel J; Górka M; Kacprzyk P; Dutka M; Rodzaj M; Bołkun Ł; Krochmalczyk D; Łątka E; Drozd-Sokołowska J; Waszczuk-Gajda A; Knopińska-Posłuszny W; Kopińska A; Subocz E; Masternak A; Guzicka-Kazimierczak R; Gil L; Machowicz R; Biliński J; Giebel S; Czerw T; Dwilewicz-Trojaczek J
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):264-274.e4. PubMed ID: 30898482
[TBL] [Abstract][Full Text] [Related]
18. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
[TBL] [Abstract][Full Text] [Related]
19. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
20. Increased cardiovascular comorbidities in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia presenting with systemic inflammatory and autoimmune manifestations.
Kipfer B; Daikeler T; Kuchen S; Hallal M; Andina N; Allam R; Bonadies N
Semin Hematol; 2018 Oct; 55(4):242-247. PubMed ID: 30502853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
